Seroatlas · Human Serome Atlas

IFNA17

Interferon alpha-17

Also known as: IFN-alphaI, IFN17_HUMAN, LEIF2C1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P01571
Gene: IFNA17
Ensembl: ENSG00000234829
Chromosome: 9
Canonical length: 189 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable cytokine activity and type I interferon receptor binding activity. Predicted to be involved in several processes, including lymphocyte activation involved in immune response; response to exogenous dsRNA; and type I interferon-mediated signaling pathway. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Implicated in Crimean-Congo hemorrhagic fever and sarcoidosis. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

189 residues, UniProt reviewed canonical sequence.

>P01571|IFNA17
     1  MALSFSLLMA VLVLSYKSIC SLGCDLPQTH SLGNRRALIL LAQMGRISPF SCLKDRHDFG
    61  LPQEEFDGNQ FQKTQAISVL HEMIQQTFNL FSTEDSSAAW EQSLLEKFST ELYQQLNNLE
   121  ACVIQEVGME ETPLMNEDSI LAVRKYFQRI TLYLTEKKYS PCAWEVVRAE IMRSLSFSTN
   181  LQKILRRKD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IFNA17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 0 nTPM

Expression across tissuesHPA

Tissue

adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM
blood vessel: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hypothalamus: 0.2 nTPM
white matter: 0.2 nTPM
basal ganglia: 0.1 nTPM
cerebral cortex: 0.1 nTPM
pons: 0.1 nTPM
amygdala: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD missense Z: -2.55
DepMap mean gene effect: -0.08
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IFNA17 as an antibody target. Whether an autoantibody or antibody against IFNA17 could matter depends on whether native IFNA17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IFNA17 is annotated as secreted, so native IFNA17 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IFNA17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...